BPC-157 (Body Protection Compound) — 5mg

BPC-157 (Body Protection Compound) — 5mg
Product Specifications
Benefits
Personal responsibility notice: By purchasing this product you confirm that you do so entirely on your own initiative and at your own personal responsibility. You are fully aware of the laws and regulations applicable in your country and region regarding research chemicals.
What is BPC-157 (Body Protection Compound) — 5mg?
BPC-157 (Body Protection Compound-157) is one of the most studied research peptides in the field of tissue repair. It is a synthetic pentadecapeptide derived from a protein naturally found in human gastric juice. Each vial contains 5mg of lyophilized BPC-157, pharmaceutical grade, ≥99% purity, HPLC tested with COA. BPC-157 is particularly popular in research circles because of its broad spectrum of activity: tendon and ligament repair, muscle tissue repair, joint health and anti-inflammatory effects. In animal models it shows pronounced cytoprotective and angiogenic properties — it promotes the formation of new blood vessels, accelerating the supply of nutrients to damaged tissue. Together with TB-500, BPC-157 forms the core of the "Wolverine Stack" — a popular combination in the research community for maximum regeneration. The half-life after subcutaneous administration is estimated at 2–4 hours. In research protocols, doses of 200–500mcg per day are used, divided across one or two injections. The substance requires reconstitution with bacteriostatic water before use. For laboratory and research purposes only.
Benefits & Mechanism
PCT & Recovery
Post Cycle Therapy (PCT) is not required after BPC-157 use. The peptide has no effect on the HPTA axis or testosterone production.
Frequently Asked Questions (FAQ)
Have questions about this product, ordering, shipping or payment? Visit our dedicated FAQ page for complete answers.
View FAQScientific Research
BPC-157 is a pentadecapeptide (15 amino acids) derived from a protective protein in human gastric juice. Preclinical studies in rats consistently show repair of tendons, muscles, nerves and gastric mucosa. The compound activates NO synthase and FAK-paxillin signaling pathways. No published human clinical trials available. BPC-157 is not on the WADA prohibited list (as of April 2026).

